Язвенная болезнь двенадцатиперстной кишки:диагностика и лечение
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29: 938–46.
2. http://www.minzdravsoc.ru/docs/mzsr/letters/60
3. Makola D, Peura DA, Crowe SE. Helicobacter pylori infection and related gastrointestinal diseases. J Clin Gastroenterol 2007; 41: 548–58.
4. Rosenstock S, Jorgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut 2003; 52: 186–93.
5. Laine L, Shah A, Bemanian S.Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers.Gastroenterology 2008; 134 (7): 1836–41.
6. Amieva MR, El-Omar EM.Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134 (1): 306–23.
7. Atherton JC.The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Ann Rev Pathol 2006; 1: 63–96.
8. Camorlinga-Ponce M, Flores-Luna L, Lazcano-Ponce E et al.Age and severity of mucosal lesions influence the performance of serologic markers in Helicobacter pylori-associated gastroduodenal pathologies.Cancer Epidemiol Biomarkers Prev 2008; 17 (9): 2498–504.
9. Radziejewska I, Kisiel DG, Borzym-Kluczyk M et al. MUC 1 mucin content in gastric juice of duodenal ulcer patients: effect of Helicobacter pylori eradication therapy. Clin Exp Med 2007; 7 (2): 72–6.
10. Дe Домбал Ф.Т. Анализ симптомов болезней верхнего отдела пищеварительного тракта. Гастроэнтерология (Ред. Дж.X.Барон, Ф.Г.Муди. Пер. с англ.) 1985; I: 58–74.
11. Asaka M, Kato M, Sugiyama T et al. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 2003; 38: 339–47.
12. Ford AC, Delaney BC, Forman D et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006; CD003840.
13. Leodolter A, Kulig M, Brasch H et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1949–58.
14. Miwa H, Sakaki N, Sugano K et al. Recurrent peptic ulcers in patients following successful Helieobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter 2004; 9: 9–16.
15. Sharma VK, Sahai AV, Corder FA et al. Helicobacter pylori eradication is superior to ulcer healing with or without maintenancetherapy to prevent further ulcer haemorrhage. Aliment Pharmacol Ther 2001; 15: 1939–47.
16. Ford AC, Delaney BC, Forman D et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99: 1833–55.
17. Malfertheiner P, Megraoud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus report. Gut 2007; 56: 772–81.
18. Кучерявый Ю.А. Влияние полиморфизма гена CYP2C19 на эффективность эрадикационной терапии инфекции Helicobacter pylori. Эксперимент. клин. гастроэнтерол. 2009; 4: 128–32.
19. Оганесян Т.С. Значение полиморфизма гена интерлейкина-1β для прогноза эффективности эрадикационной терапии язвенной болезни желудка и двенадцатиперстной кишки, ассоциированной с Helicobacter pylori. Эксперимент. клин. гастроэнтерол. 2008; 4: 92–6.
20. Маев И.В., Оганесян Т.С., Кучерявый Ю.А., Сравнительная эффективность тройной антихеликобактерной терапии 1 линии при использовании препаратов пантопразола и омепразола. Леч. врач. 2010; 2: 92–5.
2. http://www.minzdravsoc.ru/docs/mzsr/letters/60
3. Makola D, Peura DA, Crowe SE. Helicobacter pylori infection and related gastrointestinal diseases. J Clin Gastroenterol 2007; 41: 548–58.
4. Rosenstock S, Jorgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut 2003; 52: 186–93.
5. Laine L, Shah A, Bemanian S.Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers.Gastroenterology 2008; 134 (7): 1836–41.
6. Amieva MR, El-Omar EM.Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134 (1): 306–23.
7. Atherton JC.The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Ann Rev Pathol 2006; 1: 63–96.
8. Camorlinga-Ponce M, Flores-Luna L, Lazcano-Ponce E et al.Age and severity of mucosal lesions influence the performance of serologic markers in Helicobacter pylori-associated gastroduodenal pathologies.Cancer Epidemiol Biomarkers Prev 2008; 17 (9): 2498–504.
9. Radziejewska I, Kisiel DG, Borzym-Kluczyk M et al. MUC 1 mucin content in gastric juice of duodenal ulcer patients: effect of Helicobacter pylori eradication therapy. Clin Exp Med 2007; 7 (2): 72–6.
10. Дe Домбал Ф.Т. Анализ симптомов болезней верхнего отдела пищеварительного тракта. Гастроэнтерология (Ред. Дж.X.Барон, Ф.Г.Муди. Пер. с англ.) 1985; I: 58–74.
11. Asaka M, Kato M, Sugiyama T et al. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 2003; 38: 339–47.
12. Ford AC, Delaney BC, Forman D et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006; CD003840.
13. Leodolter A, Kulig M, Brasch H et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1949–58.
14. Miwa H, Sakaki N, Sugano K et al. Recurrent peptic ulcers in patients following successful Helieobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter 2004; 9: 9–16.
15. Sharma VK, Sahai AV, Corder FA et al. Helicobacter pylori eradication is superior to ulcer healing with or without maintenancetherapy to prevent further ulcer haemorrhage. Aliment Pharmacol Ther 2001; 15: 1939–47.
16. Ford AC, Delaney BC, Forman D et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99: 1833–55.
17. Malfertheiner P, Megraoud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus report. Gut 2007; 56: 772–81.
18. Кучерявый Ю.А. Влияние полиморфизма гена CYP2C19 на эффективность эрадикационной терапии инфекции Helicobacter pylori. Эксперимент. клин. гастроэнтерол. 2009; 4: 128–32.
19. Оганесян Т.С. Значение полиморфизма гена интерлейкина-1β для прогноза эффективности эрадикационной терапии язвенной болезни желудка и двенадцатиперстной кишки, ассоциированной с Helicobacter pylori. Эксперимент. клин. гастроэнтерол. 2008; 4: 92–6.
20. Маев И.В., Оганесян Т.С., Кучерявый Ю.А., Сравнительная эффективность тройной антихеликобактерной терапии 1 линии при использовании препаратов пантопразола и омепразола. Леч. врач. 2010; 2: 92–5.
Авторы
И.В.Маев, Т.С.Оганесян, Ю.А.Кучерявый
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.